메뉴 건너뛰기




Volumn 100, Issue 11, 2015, Pages E1437-E1445

Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CHGA PROTEIN, HUMAN; CHROMOGRANIN A; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN; TUMOR MARKER;

EID: 84958641689     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2792     Document Type: Article
Times cited : (99)

References (39)
  • 1
    • 37449029464 scopus 로고    scopus 로고
    • Gastroenteropancreatic neuroendocrine tumours
    • Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
    • (2008) Lancet Oncol , vol.9 , pp. 61-72
    • Modlin, I.M.1    Oberg, K.2    Chung, D.C.3
  • 2
    • 69749113601 scopus 로고    scopus 로고
    • ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification
    • Klöppel G, Couvelard A, Perren A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90:162-166.
    • (2009) Neuroendocrinology , vol.90 , pp. 162-166
    • Klöppel, G.1    Couvelard, A.2    Perren, A.3
  • 4
    • 84873375319 scopus 로고    scopus 로고
    • Systemic therapeutic options for carcinoid
    • Pavel M, Kidd M, Modlin I. Systemic therapeutic options for carcinoid. Semin Oncol. 2013;40:84-99.
    • (2013) Semin Oncol , vol.40 , pp. 84-99
    • Pavel, M.1    Kidd, M.2    Modlin, I.3
  • 5
    • 84876103467 scopus 로고    scopus 로고
    • Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
    • Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012;26:791-802.
    • (2012) Best Pract Res Clin Gastroenterol , vol.26 , pp. 791-802
    • Kanakis, G.1    Kaltsas, G.2
  • 6
    • 84881558928 scopus 로고    scopus 로고
    • Improving the diagnosis and management of neuroendocrine tumors: Utilizing new advances in biomarker and molecular imaging science
    • Giandomenico V, Modlin IM, Pontén F, et al. Improving the diagnosis and management of neuroendocrine tumors: Utilizing new advances in biomarker and molecular imaging science. Neuroendocrinology. 2013;98:16-30.
    • (2013) Neuroendocrinology , vol.98 , pp. 16-30
    • Giandomenico, V.1    Modlin, I.M.2    Pontén, F.3
  • 7
    • 84871612736 scopus 로고    scopus 로고
    • Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: The challenges ahead
    • Sundin A, Rockall A. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: The challenges ahead. Neuroendocrinology. 2012;96:261-271.
    • (2012) Neuroendocrinology , vol.96 , pp. 261-271
    • Sundin, A.1    Rockall, A.2
  • 8
    • 84857815160 scopus 로고    scopus 로고
    • ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: Well-differentiated pancreatic non-functioning tumors
    • Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: Well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95:120-134.
    • (2012) Neuroendocrinology , vol.95 , pp. 120-134
    • Falconi, M.1    Bartsch, D.K.2    Eriksson, B.3
  • 9
    • 84938539612 scopus 로고    scopus 로고
    • The future of nuclear medicine imaging of neuroendocrine tumors: On a clear day one might see forever
    • Bodei L, Kidd M, Prasad V, Baum RP, Drozdov I, Modlin IM. The future of nuclear medicine imaging of neuroendocrine tumors: On a clear day one might see forever. Eur J Nucl Med Mol Imaging. 2014; 41(12):2189-2193.
    • (2014) Eur J Nucl Med Mol Imaging , vol.41 , Issue.12 , pp. 2189-2193
    • Bodei, L.1    Kidd, M.2    Prasad, V.3    Baum, R.P.4    Drozdov, I.5    Modlin, I.M.6
  • 11
    • 84867413693 scopus 로고    scopus 로고
    • Neuroendocrine tumor disease: An evolving landscape
    • Frilling A, Akerström G, Falconi M, et al. Neuroendocrine tumor disease: An evolving landscape. Endocr Relat Cancer. 2012;19: R163-R185.
    • (2012) Endocr Relat Cancer , vol.19 , pp. R163-R185
    • Frilling, A.1    Akerström, G.2    Falconi, M.3
  • 13
    • 84857852641 scopus 로고    scopus 로고
    • Limitations of Chromogranin A in clinical practice
    • Marotta V, Nuzzo V, Ferrara T, et al. Limitations of Chromogranin A in clinical practice. Biomarkers. 2012;17:186-191.
    • (2012) Biomarkers , vol.17 , pp. 186-191
    • Marotta, V.1    Nuzzo, V.2    Ferrara, T.3
  • 14
    • 79952308016 scopus 로고    scopus 로고
    • Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting
    • Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011;29:934-943.
    • (2011) J Clin Oncol , vol.29 , pp. 934-943
    • Kulke, M.H.1    Siu, L.L.2    Tepper, J.E.3
  • 15
    • 67349181854 scopus 로고    scopus 로고
    • Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors
    • Welin S, Stridsberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology. 2009; 89:302-307.
    • (2009) Neuroendocrinology , vol.89 , pp. 302-307
    • Welin, S.1    Stridsberg, M.2    Cunningham, J.3
  • 16
    • 84940109492 scopus 로고    scopus 로고
    • Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status
    • Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 2015;22(4):561-575.
    • (2015) Endocr Relat Cancer , vol.22 , Issue.4 , pp. 561-575
    • Kidd, M.1    Drozdov, I.2    Modlin, I.3
  • 17
    • 84905994529 scopus 로고    scopus 로고
    • A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection
    • Modlin IM, Drozdov I, Alaimo D, et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr Relat Cancer. 2014;21:615-628.
    • (2014) Endocr Relat Cancer , vol.21 , pp. 615-628
    • Modlin, I.M.1    Drozdov, I.2    Alaimo, D.3
  • 18
    • 0032883399 scopus 로고    scopus 로고
    • The interpretation of diagnostic tests
    • Shapiro DE. The interpretation of diagnostic tests. Stat Methods Med Res. 1999;8:113-134.
    • (1999) Stat Methods Med Res , vol.8 , pp. 113-134
    • Shapiro, D.E.1
  • 19
    • 0038004636 scopus 로고    scopus 로고
    • Clinical biomarkers in drug discovery and development
    • Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2:566-580.
    • (2003) Nat Rev Drug Discov , vol.2 , pp. 566-580
    • Frank, R.1    Hargreaves, R.2
  • 20
    • 84904253184 scopus 로고    scopus 로고
    • Lanreotide in metastatic enteropancreatic neuroendocrine tumors
    • Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.NEngl J Med. 2014;371: 224-233.
    • (2014) N Engl J Med , vol.371 , pp. 224-233
    • Caplin, M.E.1    Pavel, M.2    Ćwikła, J.B.3
  • 21
    • 70350442637 scopus 로고    scopus 로고
    • Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group
    • Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
    • (2009) J Clin Oncol , vol.27 , pp. 4656-4663
    • Rinke, A.1    Muller, H.H.2    Schade-Brittinger, C.3
  • 22
    • 46749090507 scopus 로고    scopus 로고
    • Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs
    • Ćwikła JB, Mikolajczak R, Pawlak D, et al. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. J Nucl Med. 2008;49:1060-1065.
    • (2008) J Nucl Med , vol.49 , pp. 1060-1065
    • Ćwikła, J.B.1    Mikolajczak, R.2    Pawlak, D.3
  • 23
    • 77449132297 scopus 로고    scopus 로고
    • Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
    • Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-R73.
    • (2010) Endocr Relat Cancer , vol.17 , pp. R53-R73
    • Kwekkeboom, D.J.1    Kam, B.L.2    Van Essen, M.3
  • 24
    • 84860651877 scopus 로고    scopus 로고
    • The clinical value of MRIusing single-shot echoplanarDWIto identify liver involvement in patients with advanced gastroenteropancreatic-neuroendocrine tumors (GEP-NETs), compared to FSE T2 and FFE T1 weighted image after i.v. Gd-EOB-DTPA contrast enhancement
    • Sankowski AJ, Ćwikła JB, Nowicki ML, et al. The clinical value of MRIusing single-shot echoplanarDWIto identify liver involvement in patients with advanced gastroenteropancreatic-neuroendocrine tumors (GEP-NETs), compared to FSE T2 and FFE T1 weighted image after i.v. Gd-EOB-DTPA contrast enhancement. Med Sci Monit. 2012;18(5):MT33-MT40.
    • (2012) Med Sci Monit , vol.18 , Issue.5 , pp. MT33-MT40
    • Sankowski, A.J.1    Ćwikła, J.B.2    Nowicki, M.L.3
  • 25
    • 84877727939 scopus 로고    scopus 로고
    • The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood
    • Modlin I, Drozdov I, Kidd M. The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. Plos One. 2013;e63364.
    • (2013) Plos One , pp. e63364
    • Modlin, I.1    Drozdov, I.2    Kidd, M.3
  • 26
    • 84896130878 scopus 로고    scopus 로고
    • Gut neuroendocrine tumor blood qPCR fingerprint assay: Characteristics and reproducibility
    • Modlin I, Drozdov I, Kidd M. Gut neuroendocrine tumor blood qPCR fingerprint assay: Characteristics and reproducibility. Clin Chem. 2014;52:419-429.
    • (2014) Clin Chem , vol.52 , pp. 419-429
    • Modlin, I.1    Drozdov, I.2    Kidd, M.3
  • 27
    • 0038476015 scopus 로고    scopus 로고
    • A comparison between three commercial kits for chromogranin A measurements
    • Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003;177:337-341.
    • (2003) J Endocrinol , vol.177 , pp. 337-341
    • Stridsberg, M.1    Eriksson, B.2    Oberg, K.3    Janson, E.T.4
  • 28
    • 0028874025 scopus 로고
    • Measurements of chromogranin A, chromogranin B (secretogranin I), chromograninC( secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours
    • Stridsberg M, Oberg K, Li Q, Engström U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromograninC( secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144:49-59.
    • (1995) J Endocrinol , vol.144 , pp. 49-59
    • Stridsberg, M.1    Oberg, K.2    Li, Q.3    Engström, U.4    Lundqvist, G.5
  • 30
    • 0020083498 scopus 로고
    • The meaning and use of the area under a receiver operating characteristic (ROC) curve
    • Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143:29-36.
    • (1982) Radiology , vol.143 , pp. 29-36
    • Hanley, J.A.1    McNeil, B.J.2
  • 31
    • 0020524559 scopus 로고
    • A method of comparing the areas under receiver operating characteristic curves derived from the same cases
    • Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
    • (1983) Radiology , vol.148 , pp. 839-843
    • Hanley, J.A.1    McNeil, B.J.2
  • 32
    • 84903604456 scopus 로고    scopus 로고
    • Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: State of the art
    • de Mestier L, Dromain C, d'Assignies G, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: State of the art. Endocr Relat Cancer. 2014;21:R105-R120.
    • (2014) Endocr Relat Cancer , vol.21 , pp. R105-R120
    • De Mestier, L.1    Dromain, C.2    D'Assignies, G.3
  • 33
    • 82155166331 scopus 로고    scopus 로고
    • Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors
    • Lindholm DP, Oberg K. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors. Horm Metab Res. 2011;43(12):832-837.
    • (2011) Horm Metab Res , vol.43 , Issue.12 , pp. 832-837
    • Lindholm, D.P.1    Oberg, K.2
  • 34
    • 80054812132 scopus 로고    scopus 로고
    • Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours
    • Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18 Suppl 1:S17-S25.
    • (2011) Endocr Relat Cancer , vol.18 , pp. S17-S25
    • Oberg, K.1
  • 35
    • 77956338644 scopus 로고    scopus 로고
    • Plasma chromogranin A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
    • Massironi S, Conte D, Sciola V, et al. Plasma chromogranin A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol. 2010;105:2072-2078.
    • (2010) Am J Gastroenterol , vol.105 , pp. 2072-2078
    • Massironi, S.1    Conte, D.2    Sciola, V.3
  • 36
    • 84922396916 scopus 로고    scopus 로고
    • Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms:Alarge series from a single institution
    • Massironi S, Rossi RE, Casazza G, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms:Alarge series from a single institution. Neuroendocrinology. 2014;100:240-249.
    • (2014) Neuroendocrinology , vol.100 , pp. 240-249
    • Massironi, S.1    Rossi, R.E.2    Casazza, G.3
  • 37
    • 84871379143 scopus 로고    scopus 로고
    • Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors
    • Jensen KH, Hilsted L, Jensen C, Mynster T, Rehfeld JF, Knigge U. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scand J Gastroenterol. 2013; 48:70-77.
    • (2013) Scand J Gastroenterol , vol.48 , pp. 70-77
    • Jensen, K.H.1    Hilsted, L.2    Jensen, C.3    Mynster, T.4    Rehfeld, J.F.5    Knigge, U.6
  • 38
    • 84903614285 scopus 로고    scopus 로고
    • The 2010 WHO classification of digestive neuroendocrine neoplasms: A critical appraisal four years after its introduction
    • Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: A critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186-192.
    • (2014) Endocr Pathol , vol.25 , pp. 186-192
    • Rindi, G.1    Petrone, G.2    Inzani, F.3
  • 39
    • 33845479732 scopus 로고    scopus 로고
    • Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET)
    • Whitman HH 3rd, Fishman EK, Oberg K, Wildman JM, Long AL. Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET). Ann N Y Acad Sci. 2006;1073:59-78.
    • (2006) Ann N y Acad Sci , vol.1073 , pp. 59-78
    • Whitman, H.H.1    Fishman, E.K.2    Oberg, K.3    Wildman, J.M.4    Long, A.L.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.